Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $5.2 million.

  • Amylyx Pharmaceuticals' Cash from Investing Activities fell 8651.07% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.6 million, marking a year-over-year increase of 5681.19%. This contributed to the annual value of $75.7 million for FY2024, which is 1781.47% down from last year.
  • Amylyx Pharmaceuticals' Cash from Investing Activities amounted to $5.2 million in Q3 2025, which was down 8651.07% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Cash from Investing Activities ranged from a high of $123.2 million in Q2 2023 and a low of -$228.2 million during Q4 2022
  • Over the past 5 years, Amylyx Pharmaceuticals' median Cash from Investing Activities value was $3.6 million (recorded in 2021), while the average stood at -$7.4 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Cash from Investing Activities crashed by 70926428.57% in 2022, and later surged by 266158.67% in 2023.
  • Amylyx Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $2.8 million in 2021, then tumbled by 8208.74% to -$228.2 million in 2022, then soared by 109.17% to $20.9 million in 2023, then surged by 210.54% to $65.0 million in 2024, then tumbled by 91.94% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $23.0 million for Q2 2025, and -$43.7 million during Q1 2025.